These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 34920809)

  • 61. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
    Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY
    Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241
    [TBL] [Abstract][Full Text] [Related]  

  • 63. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 65. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
    Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
    Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
    Xu J; Ming X; Wang C; Xu B; Xiao Y
    Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment].
    Croizier C; Van de Wyngaert Z
    Bull Cancer; 2022 Feb; 109(2):113-114. PubMed ID: 35063182
    [No Abstract]   [Full Text] [Related]  

  • 68. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 69. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.
    Feinberg D; Paul B; Kang Y
    Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Future therapeutic strategies for multiple myeloma].
    Ishida T
    Rinsho Ketsueki; 2022; 63(6):635-645. PubMed ID: 35831199
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
    Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG
    Expert Opin Biol Ther; 2024 May; 24(5):339-350. PubMed ID: 38738379
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 73. GPRC5D-Directed CAR Yields 100% Response Rate.
    Cancer Discov; 2022 Aug; 12(8):OF3. PubMed ID: 35748592
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
    Parikh RH; Lonial S
    CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma].
    Goto H
    Rinsho Ketsueki; 2022; 63(6):580-588. PubMed ID: 35831191
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [CAR-T therapy for multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2023; 64(11):1456-1464. PubMed ID: 38072434
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
    Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma.
    Tang F; Lu Y; Ge Y; Shang J; Zhu X
    J Int Med Res; 2020 Jan; 48(1):300060519893496. PubMed ID: 31939323
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.
    Hanssens H; Meeus F; Gesquiere EL; Puttemans J; De Vlaeminck Y; De Veirman K; Breckpot K; Devoogdt N
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891821
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CARs and other T cell therapies for MM: The clinical experience.
    Danhof S; Hudecek M; Smith EL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):147-157. PubMed ID: 29909915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.